President and Chief Executive Officer
Wolfgang is an executive and serial entrepreneur in healthcare (diagnostics, medical devices, and health services). Currently he serves as Chairman and CEO of TOMA Biosciences, Inc., a fast growing genomic cancer diagnostic company. Previously Wolfgang was President/CEO of companies Knome (genome interpretation), Castlewood Surgical (heart bypass surgery), Boston Heart Lab (heart diagnostic / Lipidology, and now under Bain one of the fastest growing diagnostic companies in the US), BrainVital (epilepsy), Thermonix (in-stent restenosis), CardioTools (angiography), and Daum (MRI); and relocated with a company acquisition from Germany to the US in 2001. Wolfgang holds a M.S. in Physics from University of Göttingen and a PhD from Technical University Hamburg-Harburg, both Germany. He is a Board member of medical company Precisis and an active angel investor with Launchpad Angels in Boston.
Chief Technology Officer
Mike Lucero has over 25 years of experience helping to revolutionize life science tools. He was VP of PCR at Applied Biosystems (now Thermo Fisher) and has successfully built and developed multiple PCR platform tools including digital PCR and real time PCR. As an Executive VP at Fluidigm (FLDM), Mike was responsible for business development and product definition. He led the commercialization of technology at Stokes Bio as CEO, which was acquired by Applied Biosystems in 2010. Most recently, as VP of Sales and Marketing, Mike led commercialization for QuantaLife, which was acquired by Bio-Rad.
Chief Financial Officer
Asha Rajagopal joined the TOMA Biosciences management team as Acting CFO with 30 years of experience in public accounting and private industry. She has provided financial and accounting leadership for companies at every stage of growth from young driven entrepreneurial venture backed companies to large multinational firms. She has extensive experience leading companies through complex transactions including private and public financing as well as mergers and acquisitions. Asha received her BSBA in Accounting from the University of Texas and is a licensed CPA in California.
Vice President of Business Development
With more than 18 years of experience, Greg leads business development and commercial operations. He has been instrumental in shaping the commercial model and raising capital since TOMA’s founding. His passion for finding new oncology treatment options for patients began while part of the proteomics team at Myriad Genetics a cancer diagnostics pioneer. In addition to finance, sales and marketing experience, Greg gained deep oncology experience while leading teams through the evaluation process of new oncology therapeutic development programs at Genentech (Roche), and advising global pharmaceutical clients as a consultant at IMS Consulting Group and in Ernst & Young’s life science practice. He graduated from the University of Utah in Human Biology and received a Masters of Science in Business Management from the Stanford Graduate School of Business as a Sloan Fellow with an emphasis in new venture formation.
Francisco M. De La Vega, D.Sc.
VP of Bioinformatics
Francisco is a pioneer and recognized leader in bioinformatics and genomics. He is an expert in NGS data analysis, having led the development of analysis algorithms for the SOLiD system while at Applied Biosystems and later for Illumina at Real Time Genomics. He is also a contributor in key in large scale cancer and population genome sequencing projects such as the International Cancer Genome Consortium, the 1000 Genomes Project, and the NIST-led Genome-in-a-Bottle standardization consortium. Before joining TOMA he was most recently Chief Scientific Officer at Annai Systems, a big genomics data informatics start-up, and previously held technical executive positions at Real Time Genomics, Omicia, Life Technologies, and Applied Biosystems, where he spent 13 years. He also holds a Consulting Professor appointment at the Department of Genetics of the Stanford University School of Medicine. Francisco earned a Doctorate in Science degree in Genetics and Molecular Biology from the Centro de Investigacion y Estudios Avanzados of Mexico and an Executive Certificate in Management and Leadership from MIT.
Federico Goodsaid, Ph.D.
Sr. VP Clinical & Regulatory Affairs
Federico is a regulatory executive with extensive FDA and pharmaceutical industry experience in the development of optimized and novel regulatory strategies and policies for precision medicine products. His experience leads to efficient regulatory pathways for product approval by regulatory agencies throughout the world. Specific areas of expertise include: breakthrough therapies, rare diseases, surrogate endpoints and companion diagnostics.
As Vice President for Assay Development and Regulatory Affairs at TOMA Biosciences, he works on the development and regulatory submission of Next-Generation Sequencing reagents for DNA in liquid biopsy samples in oncology. As Vice President for Strategic Regulatory Intelligence at Vertex Pharmaceuticals, he focused on early and effective collaborative interactions with regulatory agencies on exploratory, enrichment and surrogate biomarkers. Before his work at Vertex, he was Associate Director for Operations in Genomics and Biomarker Qualification Coordinator at the Office of Clinical Pharmacology/Office of Translational Sciences/ Center for Drug Evaluation and Research/ U.S. FDA, working on the regulatory application and development of genomics and biomarkers at the FDA.
His B.A. was in Biochemistry and Biophysics from the University of California at Berkeley and his Ph.D from Yale University in Molecular Biophysics and Biochemistry. He was a Postdoctoral Fellow at Cornell University and at Washington University in St. Louis. Before he joined the FDA, he was Senior Staff Scientist at Applied Biosystems and Lead for the Molecular Toxicology Group at the Schering-Plough Research Institute.